Lachance Carrie
Known title: President and COOCIK: 0001790024
Lachance Carrie's purchase track record
Lachance Carrie has only 2 open-market purchases with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 5/8/2026 | INFU | $26K | +48.5% | pending | — |
| 5/15/2025 | INFU | $19K | +58.8% | +69.3% | +13.9% |
| 3/17/2023 | INFU | $20K | +43.9% | +52.8% | +13.6% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Transaction History
| INFU | ▼ Sell | Tax Withholding | 3,515 | $31K | 5/18/2026 | View on chart |
| INFU | ▲ Buy | Option Exercise | 8,932 | $0 | 5/18/2026 | View on chart |
| INFU | ▲ Buy | Grant | 21,855 | $0 | 5/17/2026 | View on chart |
| INFU | ▼ Sell | Tax Withholding | 5,322 | $47K | 5/17/2026 | View on chart |
| INFU | ▲ Buy | Option Exercise | 10,418 | $0 | 5/16/2026 | View on chart |
| INFU | ▼ Sell | Tax Withholding | 4,100 | $36K | 5/16/2026 | View on chart |
| INFU | ▲ Buy | Open Market | 1,000 | $8K | 5/11/2026 | View on chart |
| INFU | ▲ Buy | Open Market | 2,000 | $18K | 5/8/2026 | View on chart |
| INFU | ▲ Buy | Grant | 50,000 | $0 | 9/23/2025 | View on chart |
| INFU | ▼ Sell | Tax Withholding | 19,675 | $201K | 9/23/2025 | View on chart |
| INFU | ▼ Sell | Tax Withholding | 6,090 | $37K | 5/17/2025 | View on chart |
| INFU | ▲ Buy | Option Exercise | 17,727 | $0 | 5/17/2025 | View on chart |
| INFU | ▲ Buy | Open Market | 1,967 | $12K | 5/16/2025 | View on chart |
| INFU | ▲ Buy | Open Market | 1,165 | $7K | 5/15/2025 | View on chart |
| INFU | ▼ Sell | Tax Withholding | 3,179 | $20K | 5/18/2024 | View on chart |
| INFU | ▲ Buy | Option Exercise | 8,077 | $0 | 5/18/2024 | View on chart |
| INFU | ▲ Buy | Grant | 5,052 | $0 | 5/17/2024 | View on chart |
| INFU | ▼ Sell | Tax Withholding | 1,988 | $13K | 5/17/2024 | View on chart |
| INFU | ▲ Buy | Option Exercise | 50,000 | $0 | 3/1/2024 | View on chart |
| INFU | ▼ Sell | Tax Withholding | 20,032 | $186K | 3/1/2024 | View on chart |
| INFU | ▲ Buy | Option Exercise | 25,000 | $84K | 6/30/2023 | View on chart |
| INFU | ▼ Sell | Tax Withholding | 12,729 | $122K | 6/30/2023 | View on chart |
| INFU | ▲ Buy | Open Market | 3,000 | $20K | 3/17/2023 | View on chart |
| INFU | ▲ Buy | Option Exercise | 10,000 | $20K | 9/2/2022 | View on chart |
| INFU | ▼ Sell | Tax Withholding | 4,364 | $34K | 9/2/2022 | View on chart |
| INFU | ▼ Sell | Tax Withholding | 3,273 | $25K | 9/2/2022 | View on chart |
| INFU | ▲ Buy | Option Exercise | 7,500 | $15K | 9/2/2022 | View on chart |
| INFU | ▲ Buy | Grant | 10,000 | $0 | 5/20/2022 | View on chart |
| INFU | ▼ Sell | Tax Withholding | 3,935 | $33K | 5/20/2022 | View on chart |
| INFU | ▲ Buy | Grant | 4,700 | $0 | 5/20/2022 | View on chart |
| INFU | ▼ Sell | Tax Withholding | 1,850 | $16K | 5/20/2022 | View on chart |
| INFU | ▲ Buy | Option Exercise | 2,821 | $0 | 5/18/2022 | View on chart |
| INFU | ▼ Sell | Tax Withholding | 1,111 | $9K | 5/18/2022 | View on chart |
| INFU | ▼ Sell | Tax Withholding | 3,805 | $32K | 5/18/2022 | View on chart |
| INFU | ▲ Buy | Grant | 9,744 | $0 | 5/18/2022 | View on chart |
| INFU | ▲ Buy | Option Exercise | 10,000 | $0 | 11/1/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 27, 2026
INFU Shares Business Overview, Emphasizes Patient-First Strategy
INFU held a discussion outlining its business model and growth plans, highlighting a patient‑first approach to its services. The company emphasized expanding its product portfolio and improving customer engagement. The talk comes as the stock is near a key support level and shows moderate momentum. Analysts see upside potential, with a target range of $15‑$18.
INFU Shares Business Overview, Emphasizes Patient-First Strategy. INFU held a discussion outlining its business model and growth plans, highlighting a patient‑first approach to its services. The company emphasized expanding its product portfolio and improving customer engagement. The talk comes as the stock is near a key support level and shows moderate momentum. Analysts see upside potential, with a target range of $15‑$18.